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Narcolepsy is a chronic neurodegenerative disease caused by a deﬁciency of orexin-
producing neurons in the lateral hypothalamus. It is clinically characterized by excessive
daytime sleepiness and by intrusions into wakefulness of physiological aspects of rapid
eye movement sleep such as cataplexy, sleep paralysis, and hypnagogic hallucinations.
The major pathophysiology of narcolepsy has been recently described on the bases of
the discovery of the neuropeptides named orexins (hypocretins) in 1998; considerable evi-
dence, summarized below, demonstrates that narcolepsy is the result of alterations in
the genes involved in the pathology of the orexin ligand or its receptor. Deﬁcient orexin
transmission is sufﬁcient to produce narcolepsy, as we describe here, animal models with
dysregulated orexin signaling exhibit a narcolepsy-like phenotype. Remarkably, these nar-
coleptic models have different alterations of the orexinergic circuit, this diversity provide
us with the means for making comparison, and have a better understanding of orexin-cell
physiology. It is of particular interest that the most remarkable ﬁndings regarding this sleep
disorder were fortuitous and due to keen observations. Sleep is a highly intricate and regu-
lated state, and narcolepsy is a disorder that still remains as one of the unsolved mysteries
in science. Nevertheless, advances and development of technology in neuroscience will
provide us with the necessary tools to unravel the narcolepsy puzzle in the near future.
Through an evaluation of the scientiﬁc literature we traced an updated picture of narcolepsy
and orexins in order to provide insight into the means by which neurobiological knowledge
is constructed.
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HISTORICAL ASPECTS OF NARCOLEPSY
The term narcolepsy derives from the french word “narcolepsie”
created by the physician Jean-Baptiste-Édouard Gélineau by com-
bining the Greek να´ρκη (narke¯, “numbness” or “stupor”), and
λα´ψις (lepsis, “attack” or “seizure”). Even though Narcolepsy was
ﬁrst described over 120 years ago (Fisher, 1878; Gélineau, 1880;
Westphal, 1887; Löwenfeld, 1902), only in the last decade the
underlying neurobiology started to become clear.
Narcolepsy affects approximately 0.2% of the population
worldwide and causes disability in 24% of the affected subjects
(Longstreth et al., 2007). Narcoleptic patients frequently have
severe sleepiness which makes particularly difﬁcult remaining
awake during activities that demand an alert state. In addition,
these individuals regularly have fragments of rapid eye movement
(REM) sleep that intrude into wakefulness, such as dream-like
hallucinations (hypnagogic) as they drift off to sleep and cata-
plexy or have brief episodes of muscle paralysis triggered by strong
emotions.
All narcoleptic subjects present chronic sleepiness, but the
intensity varies across the day andbetween individuals. This sleepi-
ness is most troublesome during periods of inactivity, though is
often improved temporarily by a brief nap. As a consequence of
sleepiness, patients may report inattention, poor memory, blurry
vision, diplopia, and automatic behaviors such as driving without
awareness (Broughton et al., 1998; Harsh et al., 2000).
Hypnagogic hallucinations are dream-like, often frightening
hallucinations that typically occur with drowsiness or the onset
of sleep. These hallucinations are usually visual, but also tactile,
auditory, or even vestibular with a sense of sudden falling are not
uncommon.
Sleep paralysis is profound weakness occuring at the onset
of sleep or upon awakening, an intrusion of REM sleep paral-
ysis into wakefulness, and can be associated with a sensa-
tion of fear or suffocation. Hypnagogic hallucinations and
sleep paralysis are not speciﬁc to narcolepsy and can be
seen with other conditions of increased sleep pressure such
as chronic sleep deprivation or obstructive sleep apnea, and
occasionally in normal individuals (Dahlitz and Parkes, 1993;
Aldrich, 1996).
Cataplexy is a sudden muscle weakness brought on by strong
emotions, particularly joking, laughter, or anger (Guilleminault
and Gelb, 1995; Anic-Labat et al., 1999). Most likely, this also is
an intrusion of REM sleep atonia into wakefulness, but in con-
trast with sleep paralysis, cataplexy occurs almost exclusively in
narcolepsy. Consciousness is never impaired unless the patient
subsequently falls asleep or begins having hypnagogic halluci-
nations. Episodes of cataplexy may begin with clonic inhibitory
movements leading to a fall, followed by a period of atonia and
arreﬂexia usually lasting less than 2min (Rubboli et al., 2000). Cat-
aplexy may result from excessive activation of descending motor
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inhibitory pathways that are active during strong emotions orREM
sleep (Siegel et al., 1991).
HYPOTHALAMUS AND SLEEP
For years, the notion that narcolepsy was caused by some dys-
function of the hypothalamus or REM sleep-regulating pathways
existed, but the fundamental neuropathology has remained a
mystery until the last few years.
The ﬁrst correlation between the hypothalamus and sleep reg-
ulation was characterized by the Viennese neurologist Constan-
tin von Economo during the 1915 Spanish inﬂuenza epidemic
which allowed the pathoanatomical study of brain specimens
from patients who had died of encephalitis lethargica (Economo,
1917). The frequent occurrence of pathologically increased sleep
in encephalitis lethargica secondary to lesions in the posterior
hypothalamus or at the junction of the brainstem and fore-
brain, prompted him to assume that an ascending arousal system
originating in the brainstem that kept the forebrain awake existed.
This belief would be later conﬁrmed by Moruzzi and Magoun
(1949), they found that stimulation of the reticular formation of
the brain stem evoked changes in the EEG, consisting of aboli-
tion of synchronized discharge and introduction of low voltage
fast activity in its place, awakening animals from normal sleep;
which developed the concept of the“ascending activating reticular
system.”
Circling back to Von Economo’s ﬁndings, he also established
that patients who had experienced sleeplessness before dying had
brain lesions in the preoptic area of the anterior hypothalamus,
area which came to be known as the “sleep center.”
REM SLEEP AND NARCOLEPSY
The dissection of the mechanisms involved in the regulation of
sleep-wake cycling provided a better understanding of the nature
of narcolepsy.
Discovery of REM sleep by Aserinsky and Kleitman (1953) was
one of the most valuable breakthroughs regarding sleep research.
They described that this novel sleep stage had an EEG pattern
that resembled the vigilance state, occurred in a recurrent interval
and presented characteristic REM with muscle atonia, suggesting
that these physiological phenomena, and probably dreaming,were
very likely all manifestations of a particular level of cortical activ-
ity which is encountered normally during sleep (Aserinsky and
Kleitman, 1953). With this ﬁnding, they placed the last piece of
the puzzle of sleep architecture.
The early descriptions of REM sleep and its associated atonia
led multiple investigators to study sleep onset in narcolepsy. Vogel
was the ﬁrst to report REM sleep at sleep onset in a narcoleptic
patient, establishing the close relationship between REM sleep and
narcolepsy (Vogel, 1976). However, regardless of having mapped
the structural design of the sleep-wake cycle (SWC), the factual
nature of narcolepsy was not established hitherto.
THE MIDBRAIN RETICULAR FORMATION AND ITS CHEMICAL
NATURE IN SLEEP
The consensus notion that sleep resulted from active inhibition
of the vigilance midbrain reticular neurons located in the rostral
part of the brainstem gave Hernández–Peón’s group the notion
that presynaptic hypnogenic inhibitory terminals were located in
the same anatomical region.
By administering a perfused substance from a sleep-deprived
donor cat obtained from the midbrain reticular formation (MRF)
into the MRF of an awaked recipient cat, the latter began to
show the typical behavioral preparatory attitudeof sleep (Drucker-
Colín et al., 1970; Drucker-Colín, 1973). The results showed that
the MRF was a speciﬁc area of the brain involved in the regulation
of the SWCand gave the stepping stone to the discovery of the neu-
rotransmitters involved in the maintenance of sleep and vigilance.
Nowadays, we know that an alert, active, and responsive awake
state depends upon inﬂuences ascending from the brainstem to
the cerebral cortex to stimulate cortical activation and descend-
ing from the brainstem to the spinal cord to stimulate behavioral
arousal with muscle tone (Olszewski and Baxter, 1954; Butler and
Hodos, 1996; Jones, 2008).
Amongst the neurotransmitters that regulate the SWC, acetyl-
choline (ACh) has been known to play a critical role in stimu-
lating cortical activation since very early pharmacological stud-
ies (Holmes and Jones, 1994), during waking and also in REM
sleep. Cholinergic neurons can therefore stimulate cortical activa-
tion irrespective of behavioral arousal (Gnadt and Pegram, 1986;
Hallanger et al., 1987).
Another major group is the locus coeruleus (LC) noradrener-
gic neurons, which differ from neurons of the MRF and from the
cholinergic neurons of the brainstem and basal forebrain in that
they have either excitatory or inhibitory actions upon postsynaptic
neurons, and have the capacity to directly excite the thalamo-
cortical relay neurons and the cholinergic basal–cortical neurons,
aswell as cortical pyramidal neurons throughα1-adrenergic recep-
tors (AR), while inhibiting sleep-promoting neurons through α2-
ARs (McCormick, 1992). Hence, when LC neurons are active, they
can simultaneously stimulate cortical activation and behavioral
arousal. In contrast to cholinergic neurons, LC noradrenergic neu-
rons discharge selectively during waking and cease ﬁring during
sleep to be completely off during REM sleep (Hobson et al., 1975;
Aston-Jones and Bloom, 1981).
Albeit having a general knowledge of the principal chemical
substrates that regulate the SWC, it appeared that arousal systems,
which also include histaminergic and serotonergic neurons are
highly redundant and it appears that none of them is necessary for
the maintenance of a waking state (Jones, 2003).
THE DISCOVERY OF OREXINS
One of the most important breakthroughs came with the coin-
cidently discovery by two different groups of two neuropeptides
residing in the lateral hypothalamus (LH); one group named this
peptide orexin for its presumed role in appetite whereas another
group named it hypocretin for its possible resemblance to secretin,
found by orphan receptor technologies and subtractive cDNA
cloning, respectively (de Lecea et al., 1998; Sakurai et al., 1998).
Orexins are exclusively synthesized in the LH, derived from
a single protein precursor named prepro-orexin. Prepro-orexin
is enzymatically matured into two peptides, orexin-A and
orexin-B which are 33- and 28-amino-acid peptides, respectively.
Two cloned orexin receptors OX1R and OX2R are serpentine
G-protein-coupled receptors, both of which bind orexins and are
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coupled to Ca2+ mobilization (Sakurai et al., 1998). Orexins neu-
rons project within the LH throughout the central nervous system
to nuclei involved in the control of feeding, sleep-wakefulness,
neuroendocrine homeostasis, and autonomic regulation (Peyron
et al., 1998; Marcus et al., 2001).
Orexin neurons are active during wakefulness as indicated by
the expression of Fos (Estabrooke et al., 2001), and extracellular
concentrations of orexin are higher during periods of wakefulness
(Yoshida et al., 2001). Electrophysiological recordings from the
orexin neuron region identiﬁed many wake-active neurons, with
particularly high ﬁring rates when an animal is physically active
(Steininger et al., 1999; Alam et al., 2002).
In vitro, orexin excites the LC and other aminergic neu-
rons (Hagan et al., 1999; Bayer et al., 2001; Brown et al.,
2001). In vivo, injections of orexin into the lateral ventricles
or near speciﬁc arousal regions such as the LC increase wake-
fulness and markedly suppress REM sleep (Hagan et al., 1999;
Bourgin et al., 2000).
Interestingly, the orexin neuron population was previously
described by Jouvet’s group in 1989 as prolactin-secreting neurons
(Paut-Pagano et al., 1989), later on it was described that the pro-
lactin antiserumwas recognizing an epitope carried by a particular
fragment of the prepro-orexin gene (Risold et al., 1999).
NARCOLEPSY AND OREXINS: THE MISSING ELEMENT
The interest of investigators in orexins has focused on narcolepsy,
this initiated with a bright but incidental observation. The gen-
eral rationale was that genes expressed in the hypothalamus might
have medically useful effects due to the role of the hypothalamus
in control of appetite, thirst, pituitary hormones and many other
autonomic and arousal functions. In order to determine orexin
peptides role in food consumptionYanagisawa’s group constructed
a mice with a deletion of the gene coding for prepro-orexin, as
they were originally believed to be primarily important in the
regulation of appetite. Although they did not observe signiﬁcant
changes in food consumptionbetweenwildtype andorexin knock-
out mice, they did scrutinize with video recording analysis that
orexin knockout mice displayed severe sleepiness and cataplexy
like events (Chemelli et al., 1999). This association was coinci-
dently conﬁrmed in the same year when Mignot’s group sought
to identify the gene that caused canine narcolepsy by a systematic
chromosomal analysis. They identiﬁed that dogs with inherited
narcolepsy had an exon-skipping mutation in the type OX2R gene
(Lin et al., 1999).
In follow up work, Yanagisawa’s team created mice lacking
either of the two identiﬁed orexin receptors. They found that
knockout mice of the OX2R experienced cessations of activity
which they concluded were sleep attacks. They also found that
mice deﬁcient of the OX1R had disrupted sleep but showed fewer
of the signs of narcolepsy than theOX2R knockoutmice (Chemelli
et al., 2000; Willie et al., 2003).
In order to conﬁrm if speciﬁc orexin-cell loss derives in nar-
colepsy, Shiromani’s team suggested that since orexin neurons are
located only in the LH but neither electrolytic nor pharmacolog-
ical lesions of this region have produced narcoleptic-like sleep,
speciﬁc neurons need to be destroyed. They speciﬁcally damaged
orexin neurons in the LH by means of the endogenous ligand
orexin-B conjugated to the ribosome-inactivating protein saporin.
The lesioned rats presented an increase in slow-wave sleep, REM
sleep, and REM sleep intrusions during wakefulness, characteristic
of a narcoleptic phenotype (Gerashchenko et al., 2001). How-
ever, in the vast majority of the cases, human narcolepsy is not
secondary to lesions as in saporin-lesioned rats.
Meanwhile, Yanagisawa’s group where trying to deal with this
problem, to come up with an animal model that strictly resem-
bled human narcolepsy. They generated transgenic mice in which
orexin-containing neurons are ablated by orexinergic-speciﬁc
expression of a truncated Machado–Joseph disease gene product
(ataxin-3) with an expanded polyglutamine stretch. These mice
presented a gradual orexin-cell neurodegeneration and showed
a phenotype strikingly similar to human narcolepsy, including
behavioral arrests, premature entry into REM sleep and poorly
consolidated sleep patterns (Hara et al., 2001).
OREXINS AND HUMAN NARCOLEPSY
Even though murine and canine narcolepsy were demonstrated to
be caused by alterations of the orexinergic circuit, most human
narcolepsy is not familial, is discordant in identical twins, and has
not been linked to mutations of the orexin system,Mignot’s group
sought to make this association, they measured immunoreactive
orexin in cerebrospinal ﬂuid (CSF) and reported major deﬁcien-
cies in orexin CSF levels among narcoleptic patients (110 pg/ml,
one-third of mean control value; Nishino et al., 2000) implying
either a large orexin-cell loss or a complete cessation of orexin
production in these cells.
In a parallel work they also described the virtual absence of
orexin in narcoleptic brains by means of in situ hybridization and
peptide radioimmunoassay techniques (Peyron et al., 2000). In the
same year, while Mignot’s team reported a total loss of orexinergic
neurons, Siegel reported an 85–95%decrease in orexin-containing
neurons in brains of patients with narcolepsy (Thannickal et al.,
2000). This ﬁndingwas quite selective, as theMCHneurons,which
are intermingled with the orexin cells, were completely spared,
and it probably represented cell loss rather than downregulation
of orexin expression as there was concomitant loss of other mark-
ers (dynorphin and neuronal activity-related pentraxin) of the
orexin-cell population.
Regardless of having elucidated the association of human nar-
colepsy and a deﬁcit in orexin peptide production, only in a single
narcoleptic patient has been reported a mutation of the gene
responsible for orexin production (Peyron et al., 2000). Hence,
the most widely accepted view regarding the mechanism of the
orexin deﬁciency is that a degenerative process, probably immune
in origin, selectively destroys orexin-releasing neurons, thereby
producing the clinical syndrome of narcolepsy.
LOSS OF OREXIN NEURONS: THE UNANSWERED MYSTERY
Facts have now established that narcolepsy is caused by a selective
loss of orexin signaling in the brain; however, loss of orexin signal-
ingmight not be due to a simple genetic abnormality, as narcolepsy
is in most of the cases acquired during young adulthood, and the
vast majority of people with narcolepsy do not have mutations
of the genes encoding the orexin peptides or their OX1 or OX2
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receptors (Guilleminault and Anognos, 2000). Loss of orexin sig-
nal is most likely not a simple failure in producing orexin peptides
alone.
The question that arose from this particular riddle was: what
other genesmight be altered and cause orexin neuron deﬁciency in
narcolepsy? Approximately 90% of patients with narcolepsy have
human leukocyte antigenDQB1 ∗ 0602 andDQA1 ∗ 0102 (Mignot
et al., 2001; Scammell, 2003), leading many researchers to hypoth-
esize that the loss of orexin neurons may be immune-mediated.
In order to analyze this, Mignot’s team performed gene expres-
sion proﬁling in the hypothalamus to identify novel genes dysreg-
ulated in a rodent model of narcolepsy (orexin–ataxin-3 mice),
as these could be the target of autoimmune attack or modulate
orexin gene expression. They found a novel genewhich colocalized
in orexin cells named insulin-like growth factor binding protein 3
(IGFBP3) that was dysregulated in the orexin–ataxin-3 mice and
colocalized in the remaining orexin neurons. They postulated that
excessive IGFBP3 expression might initiate orexin-cell death and
cause narcolepsy (Honda et al., 2009).
Almost simultaneously, our group was working with a mouse
carrying a deletion of the gene coding for the transcription factor
O/E3 (also called ebf2), which is normally highly expressed in the
central nervous system and regulates neuronal differentiation in
the hypothalamus. While determining the role of O/E3 in olfac-
tory circuit architecture; we observed that these O/E3-null mice
presented what appeared to be a sudden and transient episode of
loss of muscle tone during an active period of vigilance, which
indicated it could be a direct transition from vigilance to REM
sleep and that O/E3-null mice might have a narcoleptic pheno-
type. By means of electrophysiological analysis of the SWC and
immunostaining against orexin, we found that O/E3 knockout
mice presented direct transitions from vigilance to REM sleep
characteristic of a narcoleptic phenotype (Figures 1D,G) and a
fragmented SWC (Figure 1F), whereas their wildtype littermates
presented a normal sleep pattern (Figure 1E) and normal sleep
transitions (from nREM to REM, Figure 1C). Additionally, OE/3-
nullmice presented a loss of approximately 80%of orexin neurons
(Figure 1B) compared to their wildtype littermates (Figure 1A;
De la Herrán-Arita et al., 2011).
Worthy of notice, O/E3 was one of the downregulated genes
in the narcoleptic orexin–ataxin-3 mice in the work published
by Mignot’s group (Honda et al., 2009), conﬁrming that O/E3
FIGURE 1 | Decreased number of orexin-producing cells in the LH and
narcoleptic phenotype of O/E3-null mice. Orexin-A immunostaining of
brain coronal sections show orexin-producing cell bodies in the lateral
hypothalamic region of Wt animals [(A), bregma −1.70mm, 3rdV denotes the
lumen of the 3rd ventricle). In O/E3-null narcoleptic mice, orexin-A-positive
cell bodies are drastically reduced in number and are restricted to a smaller
region of the LH (B). Representative EEG/EMG recordings of transitions to
REM sleep obtained during the dark period from Wt mice reveal that REM
sleep is preceded by nREM sleep (C). Representative recordings from
O/E3-null animals show direct transitions to REM sleep (DREM), where REM
sleep is immediately preceded by an epoch of wake (D). Representative
hypnograms derived from the EEG/EMG recordings show multiple DREM
episodes occurring in O/E3-null mice (G), while none can be detected in
Wt animals (F).
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is expressed in the LH, where it might regulate prepro-orexin
gene expression. By using a sequence alignment approach we
were able to identify two conserved sequences within the pro-
moter regions of the prepro-orexin genes of four different species,
which appear to correspond to putative olf-1-responsive sequences
(De la Herrán-Arita et al., 2011). Olf-1 binding sites have been
demonstrated to serve as targets for members of the O/E tran-
scription factor family (Wang et al., 1993). One of the olf-1 sites
in the prepro-orexin gene is superposed to the OE1 element,
which suggests that O/E3 could directly regulate prepro-orexin
gene expression (Figure 2).
Taken together, the data demonstrated that O/E3 is the newest
discovered member in the regulation of orexin-cell physiology.
Interestingly, the narcoleptic phenotype of O/E3-null mice dif-
fers from orexin-null (Chemelli et al., 1999) and orexin–ataxin-3
transgenic mice (Hara et al., 2001), since O/E3-null mice have
less wakefulness, more nREM sleep and an increase in REM
sleep during the dark period (Table 1). These differences could
be partially due to the genetic background in which the dis-
tinct mutations are maintained: while the orexin-modiﬁed mouse
lines are C57BL/6 hybrids, crossed to either DBA/1 (orexin–
ataxin) or 129/SvEv (orexin knockout) strains, O/E3-null mice
are kept within a 129S2/Sv background. It has been demon-
strated that even a single chromosome substitution within a
given background can alter the SWC parameters of mouse strains
(Yang et al., 2009).
This ﬁnding brings us closer to determine the factors involved
in the regulation of the SWC and the basis of the narcolepsy–
cataplexy syndrome, which in the near future might help the
development of a proper therapeutic solution for narcolepsy.
THE STRUGGLE AGAINST OREXIN DEFICIT
Narcolepsy is now identiﬁed to be a neurodegenerative disease
characterized by a massive speciﬁc loss of orexin neurons in the
LH. Even though the cause of orexinneuronal loss is still unknown,
different approaches to revert the absence of these neuropeptides
have been attempted.
Gene transfer has proven to be an effective neurobiological
tool in a number of neurodegenerative diseases; since narcolepsy
is a disease where the orexin precursor prepro-orexin is missing,
a viral vector was constructed to transfer the gene to the LH of
orexin knockout mice. During the 4-day life-span of the vector,
the incidence of cataplexy declined by 60%, and the levels of REM
sleep were similar to wildtype mice, indicating that narcoleptic
FIGURE 2 | Presence of olf-1 (O/E3 binding site) like elements in the
promoter region of prepro-orexin genes. Alignment of the upstream
(283–300 bp) sequences of the prepro-orexin (prepro-hypocretin) locus (Hcrt)
from four separate mammals shows two highly conserved olf-1-like (olf-1/ebf,
bold face) elements. The consensus olf-1 sequence, depicted under the
alignments, was identiﬁed as an OE1 binding site in genes expressed in the
olfactory epithelium. One of these olf-1-like elements overlaps with one of the
regions (OE1, underlined) that appear to restrict prepro-orexin expression in
the lateral hypothalamus. The second olf-1-like element lies at position-7 from
the putative transcription start site (arrow indicating direction of transcription).
A conservedTATA box can also be identiﬁed at position-24 in all these genes.
Translation start site (ATG) is indicated in italics.
Table 1 | Time during the dark phase.
Murine model of Narcolepsy Stage (minute) Episode duration Additional remarks
Wake nREM REM Wake nREM REM Orexin loss Phenotype
Orexin knockout mouse 350.0±20.2 327.2±19.8 41.0±2.3 284.0±59.9 s 235.9±39.0 s 83.8±3.0 s Total Normal
Orexin–ataxin-3 mouse 384.4± 9.1 287.9±9.6 46.4±2.0 247.0±17.6 s 188.7±8.8 s 85.7±2.8 s Total Obese
Saporin-lesioned rat NA NA NA 3.8±0.5min 3.2±0.3min 1.9±0.1min >60% NA
O/E3 knockout mouse 300± 19.2 329.8±18.4 88.9±2.5 249.5±4.7 s 282.25±5.3 s 83.5±1.7 s <80% Dwarf
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sleep–wake behavior in orexin knockout mice can be improved by
targeted gene transfer (Liu et al., 2008).
In another effort to reverse the narcoleptic phenotype in a
transgenic animal, Mieda et al. (2004, 2005) produced a trans-
genic mouse that overexpress a prepro-orexin transgene under
the control of a β-actin/cytomegalovirus hybrid promoter (CAG-
orexin transgenicmice), and crossed them to orexin–ataxin-3mice
to produce offspring that carry both transgenes (double hem-
izygous mice). Their results showed that orexin–ataxin-3/CAG–
orexin double transgenic littermates exhibited longer, more con-
solidated bouts of wakefulness and normalized amounts of REM
sleep during the dark phase than their orexin–ataxin-3 littermates.
Most outstandingly, no direct transitions from vigilance to REM
sleep were ever detected in any double transgenic mice. However,
chronic overproduction of orexins in CAG–orexin mice caused
destabilization of sleep.
In a different experimental approach, they examined whether
acute intra-cerebroventricular administrations of orexin pep-
tide might also rescue the narcoleptic phenotype. When
orexin–ataxin-3 mice were administered orexin-A peptide, the
frequency of arrests and overall time spent in cataplexy were sig-
niﬁcantly reduced in a 3-h period (Mieda et al., 2004). The result
was later conﬁrmed by our research in a similar experiment where
O/E3-null mice were given the same dose of orexin-A peptide (De
la Herrán-Arita et al., 2011), however, O/E3-null mice presented a
total REM sleep abolition, probably due to the different genetic
background in which the distinct mutations were maintained.
Thus, administration of orexin-A is sufﬁcient to acutely sup-
press behavioral arrests in narcoleptic mice, but a simpler method
for administration should be developed. With these results, it is
demonstrated that high level of orexin peptides, as well as a lack
of orexins, results in an inadequate regulation of the SWC.
Given that narcolepsy is secondary to a loss of orexin-producing
neurons, a logical inference would be to replace the missing neu-
rons in order to reverse the symptoms. Following that thought,
our group decided to evaluate the survival of orexin neuron
grafts, based on the premise that studies made by others and us
have demonstrated that grafted tissue survives, integrates within
the host brain, and provides functional recovery following brain
injury in various animal models (Perlow et al., 1979; Drucker-
Colín et al., 1984; Björklund and Lindvall, 2000). By analyz-
ing the survival of orexin-containing neurons grafted into the
pontine reticular formation, a region traditionally regarded to
be essential for REM sleep generation; our group found that
orexin-immunoreactive somata with processes and varicosities
were present in the graft zone 36 days after the implant (Arias-
Carrión et al., 2004). However, efforts should be made to increase
survival of these neurons and to evaluate the effect of these grafts
in narcoleptic animals.
DISCUSSION
Key elements of narcolepsy have been revealed in the last decade.
Sleep research is an intricate area; unraveling and identifying the
mechanisms involved in the regulation of the SWC has been a
difﬁcult attempt, due its nature as an intricate system.
Identifying the cause of a sleep disorder is a complex task. Nar-
colepsy may be one of the few neurological disorders in which the
pathological process has been identiﬁed.
A giant leap in the way to unravel the mystery of this disease
was taken with the ﬁnding of orexin peptides and its association
with SWC regulation. Novel evidence demonstrates that impaired
orexin signaling is the major, if not the sole cause of the pathogen-
esis of Narcolepsy, thus contributing to the idea that it is actually
a neurodegenerative disease.
Clearly, alterations in the orexin systemare fundamental for this
disorder. Nonetheless, clariﬁcation of the mechanisms responsible
for the loss of orexinergic neurons still needs to be determined; this
may shed light on new tools for diagnosing and treating this dis-
ease and will have important implications for the comprehension
of the orexin system and analysis of human narcolepsy. Narcolep-
tic animal models will aid in solving this dilemma, the variations
between the murine narcolepsy models offer us a broad perspec-
tive of the Narcolepsy syndrome. The difference in the time spent
in each stage of the SWC in these narcoleptic animals is caused
by exclusive alterations of the orexinergic circuit. This divergence
opens new ways to fully understand how the orexinergic circuit is
formed and provides the means for a deeper analysis of the genes
that are altered in narcolepsy or implicated in orexin regulation.
Genetic proﬁle in narcolepsy may have implications for future
therapies, which might involve orexin gene therapy, transplanta-
tion of orexin neurons, stem cell precursors, or engineered cells
to produce orexin peptides. Moreover, narcolepsy can be added
to the list of the few neurologic disorders which arise from the
selective loss of a single population of neurons.
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